Vivus Analyst: The FDA Has Crossed the Rubicon of Balancing Risk and Benefit, Understanding That Obesity is a Pandemic.  There Are Not a Lot of Products That Address Such Large Market Opportunities.  Vivus Will Not Give This Up Cheaply